Lixte Biotechnology Holdings (FRA:8640) 3-Year EBITDA Growth Rate : 2.90% (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Lixte Biotechnology Holdings 3-Year EBITDA Growth Rate?

Lixte Biotechnology Holdings's EBITDA per Share for the three months ended in Dec. 2023 was €-0.42.

During the past 3 years, the average EBITDA Per Share Growth Rate was 2.90% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was -9.90% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was -3.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Lixte Biotechnology Holdings was 25.80% per year. The lowest was -55.20% per year. And the median was -9.00% per year.

Competitive Comparison of Lixte Biotechnology Holdings's 3-Year EBITDA Growth Rate

For the Biotechnology subindustry, Lixte Biotechnology Holdings's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lixte Biotechnology Holdings's 3-Year EBITDA Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lixte Biotechnology Holdings's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Lixte Biotechnology Holdings's 3-Year EBITDA Growth Rate falls into.

Lixte Biotechnology Holdings 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Lixte Biotechnology Holdings (FRA:8640) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Lixte Biotechnology Holdings 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Lixte Biotechnology Holdings's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Lixte Biotechnology Holdings (FRA:8640) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lixte Biotechnology Holdings Inc (FRA:8640) » Definitions » 3-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

LIXT:USA

Address

680 East Colorado Boulevard, Suite 180, Pasadena, CA, USA, 91101

Website

https://www.lixte.com

Lixte Biotechnology Holdings Inc is a drug discovery company that has a developed unique, proprietary, first-in-class protein phosphatase inhibitor, LB-100, as its lead clinical compound. LB-100 has potential widespread use as an anti-cancer agent when used alone and in combination with standard anti-cancer therapies, including cytotoxic drugs, radiation, and immune checkpoint blockers. The Company's product pipeline is primarily focused on inhibitors of protein phosphatases, used alone and in combination with cytotoxic agents and x-ray and immune checkpoint blockers.

Lixte Biotechnology Holdings (FRA:8640) Headlines

No Headlines